HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by LIEBERMAN, A. Articles by GOLDSTEIN, M. Search for Related Content PubMed PubMed Citation Articles by LIEBERMAN, A. Articles by GOLDSTEIN, M.

The antiparkinsonian efficacy of bromocriptine

From the Department of Neurology (Drs. Lieberman, Zolfaghari, Boal, Hassouri, and Vogel), the Department of Neurosurgery (Dr. Battista), and the Department of Psychiatry (Division of Neurochemistry) (Dr. Goldstein), New York University School of Medicine, New York, and the Department of Histology, Karolinska Institute, Stockholm (Dr. Fuxe).

The antiparkinsonian activity of bromocriptine, a presumed dopaminergic receptor agonist, was investigated in monkeys with surgically induced tremor and in a group of parkinsonian patients. A single administration of bromocriptine resulted in a dose-dependent relief of tremor in monkeys. Repeated administration enhanced this effect. Only mild abnormal involuntary movements were observed and only after repeated administration. Eleven patients with Parkinson's disease were treated with bromocriptine (mean dose, 26.4 mg a day). Clinically obvious improvement was noted in one or more of the cardinal signs of the disease in six patients (responders). No obvious improvement in any of the cardinal signs was noted in the remaining five patients (nonresponders). Clinically, the responders were older and more severely affected and had been on a higher dose of levodopa. However, they had had the disease for a shorter period. It is suggested that failure to respond to bromocriptine may be related to a decrease in the sensitivity of postsynaptic dopaminergic receptors.

Reprint requests should be addressed to Dr. Lieberman, 566 First Avenue, New York, NY 10016.

This work was supported by USPHS grants NS 06801 and MH02717 and by a grant (044-715) from the Swedish Medical Research Council.

Received for publication July 21, 1975.

This article has been cited by other articles:

				Habib-ur-Rehman Diagnosis and Management of Tremor Arch Intern Med, September 11, 2000; 160(16): 2438 - 2444. [Abstract] [Full Text]